Results 41 to 50 of about 22,003 (134)

Interferon Regulatory Factor 2 (IRF2) Suppression Enhances Murine Cardiac Allograft Survival Through Immune Evasion

Immunology, EarlyView.
Our data show that suppressing IRF2, genetically or by siRNA, modulates PD‐L1 and MHC‐I levels. This induced immune‐evasive state critically underlies the significantly prolonged survival of cardiac allografts, revealing a novel therapeutic avenue.
Li Tian, Man Zhang, Yuliang Guo, Sheng Chang, Zhonghua Klaus Chen, Hongmin Zhou   +5 more
wiley   +1 more source

C‐X‐C chemokine receptor CXCR4 mediates diurnal changes in the aggregation and dispersion of CD8+ T cells within the tumor microenvironment

International Journal of Cancer, Volume 158, Issue 6, Page 1740-1754, 15 March 2026.
What's new? In addition to governing daily variations in biological activity, the circadian clock regulates immune cell migration into tumors. Whether this influence extends to immune cell localization within the tumor microenvironment (TME) is unknown. Here, using cell and animal models, the authors investigated immune cell distribution within the TME
Akito Tsuruta, Marina Fujimoto, Yasuha Hiraoka, Aoi Taniguchi, Yuki Shiiba, Takuto Inoki, Tomoaki Yamauchi, Yuya Yoshida, Naoya Matsunaga, Shigehiro Ohdo, Satoru Koyanagi   +10 more
wiley   +1 more source

Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis. [PDF]

, 2018
Peritoneal metastasis (PM) is an advanced stage malignancy largely refractory to modern therapy. Intraperitoneal (IP) immunotherapy offers a novel approach for the control of regional disease of the peritoneal cavity by breaking immune tolerance.
Bowne, Wilbur B., Katz, Steven C., Khalili, Marian, Morano, William F., Richard, Scott D., Thadi, Anusha   +5 more
core   +2 more sources

Neuro‐Immune Crosstalk: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets

MedComm, Volume 7, Issue 2, February 2026.
Neurons, immune cells, and other cellular components within the disease microenvironment (such as stromal cells and tumor cells) constitute a dynamically evolving ecosystem. Neurons directly modulate immune cell activity and inflammatory responses through the release of neurotransmitters (e.g., norepinephrine and CGRP), while also promoting tumor ...
Xin Guo, Hui Liu, Yu‐Jing Song, Jian‐Hua Wang, Danfeng Liu, Zhi‐Wei Zheng, Jia‐Jun Li, Boya Li, An Song, Wei He, Lei‐Lei Yang, Shuo Wang   +11 more
wiley   +1 more source

TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2 [PDF]

, 2019
Background: The co-inhibitory receptor PD-1 is expressed in many tumors including head and neck squamous cell carcinoma (HNSCC) and is an important immunotherapy target.
Ahmadzadeh, Albers, Ansell, Baruah, Brahmer, Ceeraz, Dong, Forster, Gameiro, Gao, George, Gursel, Hamid, Hino, Howitt, Junttila, Kaminski, Kataoka, Kawai, Kiemer, Konishi, Krieg, Kuznik, Lastwika, Loi, Lyford-Pike, Nazareth, Nguyen, Nishimura, O'mahony, Okazaki, Pai, Pinchuk, Raposo, Saada-Bouzid, Strome, Topalian, Topalian, Velcheti, Venuti, Wilke, Wintterle, Wolchok, Wolfle, Yearley, Zou   +45 more
core   +1 more source

On the same side: VISTA and its ligands interact in cis on the cell surface

Protein Science, Volume 35, Issue 1, January 2026.
Abstract VISTA, an essential immune checkpoint protein, regulates peripheral T‐cell quiescence and tolerance. Despite its potential as a target for anti‐tumor and autoimmune disease therapies, uncertainty regarding VISTA's binding mode and membrane orientation has hindered the development of these therapies.
Karina Smorodinsky‐Atias, Gil Wiseglass, Alina Artyukhova, Mariana Salem, Maya Kashani, Nadir Boni, Rachel Levy, Rotem Rubinstein   +7 more
wiley   +1 more source

Asthma in Patients With Confirmed Pulmonary Sarcoidosis

Canadian Respiratory Journal, Volume 2026, Issue 1, 2026.
Pulmonary sarcoidosis and asthma can present identical symptoms, making clinical evaluation difficult if the two diseases overlap. Diagnostic challenges often lead to either overdiagnosis of asthma in patients with confirmed sarcoidosis or withholding appropriate asthma treatment.
Agata Anna Lewandowska, Dorota Waśniowska, Małgorzata Kołodziej, Helena Mirus-Arabik, Aleksandra Gaczkowska, Ola Duszyńska, Krzysztof Bułat, Michał Graczyk, Cezary Rybacki, Lipi Buch   +9 more
wiley   +1 more source

Alterations of immune response of non-small lung cancer with azacytidine [PDF]

, 2013
Innovative therapies are needed for advanced Non-Small Cell Lung Cancer (NSCLC). We have undertaken a genomics based, hypothesis driving, approach to query an emerging potential that epigenetic therapy may sensitize to immune checkpoint therapy targeting
Baylin, Stephen B, Brahmer, Julie R, Brock, Malcolm V, Carvajal, Richard D, De Meyer, Tim, Du, Zhengzong, Easton, Keith, Easwaran, Hariharan, Jones, Peter A, Juergens, Rosalyn A, Koch, Alexander, Laird, Peter W, Mohammad, Helai P, Pardoll, Drew, Parsana, Princy, Rodgers, Kristen, Rudin, Charles M, Taube, Janis M, Topalian, Suzanne L, Tsai, Salina, Tykodi, Scott S, Van Criekinge, Wim, Vendetti, Frank, Wang, Wei, Weisenberger, Daniel J, Wrangle, John, Yen, Ray-Whay, Zahnow, Cynthia A   +27 more
core   +1 more source

MARCO+ Tumor‐Associated Macrophages Impede CD8+ T Cell Immunity to Facilitate Immunotherapy Resistance in Renal Cell Carcinoma

Advanced Science, Volume 12, Issue 47, December 18, 2025.
MARCO+ TAMs dominate restrained cytotoxicity of CD8+ CTLs and ICB resistance in RCC. Mechanically, MARCO impairs MHC‐I‐mediated neoantigen cross‐presentation via the SOCS1‐JAK1‐STAT1‐NLRC5 signaling cascade in TAMs. Targeted MARCO treatment boosts macrophage antigen cross‐presentation and empowers CD8+ T cells, thereby potentiating ICB efficacy ...
Jiayuan Chen, Jiazhi Mo, Jinchang Wei, Mengnan Qu, Jie Dai, Yan Kong, Huayan Xu, Juan Li, Xieqiao Yan, Chuanliang Cui, Lu Si, Zhihong Chi, Jun Guo, Xiaowen Wu, Xinan Sheng   +14 more
wiley   +1 more source

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. [PDF]

, 2018
Our expanding knowledge of immunotherapy for solid tumors has led to an explosion of clinical trials aimed at urothelial carcinoma. The primary strategy is centered on unleashing the immune system by releasing the inhibitory signals propagated by ...
Chamie, Karim, Crosetti, Anna M, Cummings, Amy L, Drakaki, Alexandra, Faiena, Izak, Pantuck, Allan J   +5 more
core   +1 more source